Neurology India Medknow Publications on behalf of the Neurological Society of India ISSN: 0028-3886 EISSN: 1998-4022 Vol. 57, Num. 6, 2009, pp. 837-837

Neurology India, Vol. 57, No. 6, November-December, 2009, pp. 837

Correspondence

Mitroxantrone in multiple sclerosis

Sourabh Aggarwal

University College of Medical Sciences, New Delhi, India.
Correspondence Address: University College of Medical Sciences, New Delhi, India, drsourabh79@gmail.com

Date of Acceptance: 15-Dec-2009

Code Number: ni09244

PMID: 20139539

DOI: 10.4103/0028-3886.59504

Sir,

I read the article 'Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting' ^[1] with interest. I applaud the authors for conducting such a study in Indian setup. The beneficence of low cost involved in the treatment of multiple sclerosis with mitroxantrone need to be evaluated against the cost involved in dealing with the significant morbidity caused due to potential side effects of the drug therapy. The ethical justification of initiating such therapy in relatively milder form of disease is a matter of serious discussion and will be debated upon for a long time to come. Nonetheless, the authors have done a commendable job in view of patients seriously impaired by multiple sclerosis who cannot afford first line treatment, though large scale study will be needed to complement the results of this study.

References

1.	Singhal BS, Geeta S, Hundalani SG, Menon S. Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting. Neurol India 2009;57:418-23.  Back to cited text no. 1  [PUBMED]

Copyright 2009 - Neurology India